Hicks v. Charles Pfizer & Co. Inc.Hicks v. Charles Pfizer & Co. Inc.
MEMORANDUM AND ORDER
Pending before the court is Defendants Charles Pfizer & Company Inc., Pfizer, Ltd., and Pfizer Inc.’s (collectively, “Pfizer”) Motion for Summary Judgment (# 126). Pfizer seeks summary judgment on Plaintiffs Karen Hicks and Benny Hicks’s (“the Hicks”) personal injury action asserting claims for products liability, negligence, fraud, and breach of warranty,
I. Background
In June 2001, Karen was diagnosed with a brain tumor that she alleges was caused by OPV administered to her as a child. She was subsequently diagnosed with a second brain tumor. The Hicks contend that, during the manufacturing process, the OPV was contaminated with simian virus 40 (“SV 40”) while being cultured in tissue from monkey kidneys. SV 40 has allegedly been linked to brain tumor formation and cancer in humans. The Hicks maintain that tests on the tissue of Karen’s first tumor revealed the presence of SV 40 deoxyribo-nucleic acid.
In 1962, the Jefferson County, Texas, Medical Society (“Medical Society”) sponsored a massive public health campaign, Project XP, to vaccinate the public against polio. Free OPV was provided to any resident over six weeks of age who wished to receive the vaccine. The Project XP campaign was administered in three phases in 1962: September 9 (Type I), October 21 (Type III), and December 2 (Type II). Three drops of OPV were placed on a sugar cube that was then ingested by the recipient. Karen claims to have participated in Project XP and ingested three separate sugar cube vaccinations in 1962, when she was approximately five-years-old. Karen further alleges that she received one or two more doses of OPV from plastic dispertes at her physician’s office in 1968 and 1971.
The Hicks filed suit in the 58th Judicial District Court of Jefferson County, Texas, on February 19,. 2004, asserting .that one or more of thirty-three named defendants manufactured the OPV Karen received. On April 8, 2004, the case was removed to federal court based on the diversity of citizenship of the parties.
See
As a result of the product identification discovery, the Hicks dismissed all but ten of the defendants from this action. The remaining defendants were corporate entities related through acquisition or merger to Wyeth. Wyeth moved for summary judgment on the grounds that, after extensive product identification discovery, the Hicks could not identify who manufactured the OPV Karen received, and therefore, could not establish that Wyeth produced the vaccine in question. On March 8, 2005, this court granted Wyeth’s motion for summary judgment on the basis of product identification. The court permitted the Hicks to amend their complaint to name additional defendants, specifically certain Pfizer entities. Pfizer now argues that there is no competent evidence that Karen received its products, thus defeating the causation element of the Hicks’ claims.
A. Summary Judgment Standard
Once a proper motion has been made, the nonmoving parties may not rest upon mere allegations or denials in the pleadings but must present affirmative evidence, setting forth specific facts, to show the existence of a genuine issue for trial.
See Celotex Corp.,
Summary judgment is mandated if the nonmovants fail to make a showing sufficient to establish the existence of an element essential to their case on which they bear the burden of proof at trial.
See Nebraska v. Wyoming,
B. Product Identification
1. Causation
The Hicks pleaded this case as one arising in strict liability, negligence, fraud, and breach of warranty. In order to recover under any of these theories, the Hicks must establish the element of causation.
See In re Norplant Contraceptive Prods. Litig.,
In essence, the Hicks must prove Pfizer’s product caused Karen’s brain tumors. “A fundamental principle of traditional products liability law is that the plaintiff must prove that the defendants supplied the product which caused the injury.”
Gaulding v. Celotex Corp.,
2. Newspaper Articles and Hearsay ’ Concerns
The Hicks offer as evidence several newspaper articles, four of which link Pfizer with the doses of OPV that Karen allegedly ingested. An article dated August 9, 1962, from the Beaumont Enterprise states that “[t]he medical society has purchased the vaccine from Pfizer Laboratories.” Warren Weber, 250,000 in Jefferson Are Expected to Receive Polio Vaccine Sept. 9, Beaumont Enterprise, Aug. 9, 1962. An article from the Beaumont Journal, also dated August 9, 1962, quotes Dr. Paul Meyer, described as the director of Project XP, stating that “Pfizer Laboratories of New York will provide the vaccine .... ” Immunization Set for Sept. 9: Education Drive to Start Aug. 15 in Polio Project, Beaumont Journal, Aug. 9, 1962. An August 14, 1962, article from the Beaumont Journal states that “Southwestern Drug Corp .... will receive the live vaccine from the Pfizer Laboratories of New York....” Edythe Capreol, Drivein Station to Be Added to Clinics in Polio Drive Here, Beaumont Journal, Aug. 14, 1962. Finally, an article dated November 27, 1962, from the Beaumont Enterprise states that the vaccine “was ordered from Charles Pfizer Laboratories of New York....” Third and Final Phase of Polio Eradication Drive Slated Sunday in County, Beaumont Enterprise, Nov. 27, 1962.
The Hicks have not proffered the testimony of a person who has present, personal knowledge of the identity of the vaccine manufacturer or business records identifying the supplier of the relevant doses. Karen admits-she does not remember and, in fact, never knew the identity of the manufacturer of the polio vaccine that she ingested. Discovery directed at the defendants has not unearthed any documentation concerning the manufacturer of the relevant doses of OPV. Pfizer no longer retains any records that could potentially shed light on whether it manufactured the OPV doses at issue. Accordingly, the newspaper articles represent the only known, existing link between Pfizer and the product that allegedly caused Karen’s injury.
Pfizer contends that the newspaper accounts should not be considered as competent summary judgment evidence because the assertive statements contained therein constitute inadmissible double hearsay. Generally, newspaper articles are “classic, inadmissible hearsay” and are “unusable to defeat summary judgment.”
Roberts v. City of Shreveport,
An additional hearsay problem exists with the
Beaumont Journal
articles dated August 9, 1962, and August 14, 1962. While the articles from the
Beaumont Enterprise
refer to the vaccine being acquired in the past tense, the
Beaumont Journal
articles refer exclusively to events that will occur in the future. Nevertheless, this level of hearsay may also be excused by application of an appropriate hearsay exception.
See
a. The Ancient Documents Hearsay Exception
The Hicks assert that the ancient documents exception should be applied to render the newspaper articles admissible. This exception provides that “[statements in a document in existence twenty years or more the authenticity of which is established” are admissible.
The dangers
of
hearsay relate to flaws in perception, memory, narration, and sincerity.
See Park v. Huff,
The crucial issue, however, is whether
Courts are divided as to the proper application of
Some courts have implied that multiple levels of otherwise inadmissible hearsay may be admitted under
Better reasoned authority indicates that the ancient documents exception permits the introduction of statements only where the declarant is the author of the document. Even if a document qualifies as ancient under
b. The Residual Hearsay Exception
In the alternative, the Hicks contend that the newspaper articles are admissible under the residual hearsay exception contained in Rule 807. Rule 807 provides:
A statement not specifically covered byRule 803 or 804 but having equivalent circumstantial guarantees of trustworthiness, is not excluded by the hearsay rule, if the court determines that (A) the statement is offered as evidence of a material fact; (B) the statement is more probative on the point for which it is offered than any other evidence which the proponent can procure through reasonable efforts; and (C) the general purposes of these rules and the interests of justice will best be served by the admission of the statement into evidence.
In that case, the Fifth Circuit, after weighing the trustworthiness and necessity of the document, upheld the admission in evidence of a newspaper article detailing a fire at the local courthouse, marking an early harbinger of the residual hearsay exception.
See Dallas County,
Before admitting evidence under the residual hearsay exception, the court must find that the evidence satisfies the prerequisites of trustworthiness, notice, necessity, and materiality, and must also determine that the purposes of the rules and justice will be served by admission of the evidence.
See
(1). Trustworthiness
The statements contained in the four newspaper articles offered by the Hicks evince particularized guarantees of trustworthiness. First, as in
Dallas County,
the statements in question were made long before any motive to fabricate arose. It is completely implausible that those who provided the information contained in the articles could have anticipated the current controversy more than forty years ago or that their statements would be proffered as evidence in a court case.
See Dallas County,
Second, any other drug company that was actually supplying the vaccine would have possessed a motive to correct inaccurate public statements on this issue, given that Project XP was a high-profile, public health campaign designed to eradicate a devastating illness. Any manufacturer that supplied the vaccine would surely have cultivated the good will of the surrounding community. Had Pfizer not manufactured the vaccine, it is likely that the true manufacturer, or someone connected with Project XP, would have stepped forward to correct the misinformation contained in the newspaper articles. Indeed, the Hicks’ initial presentation of certain newspaper articles indicating that Wyeth was to supply the OPV was successfully repudi
Third, the fact that four articles, by a minimum of two different authors, in two separate newspapers, without any relation to the present controversy, all identified Pfizer as the manufacturer of the doses distributed by Project XP after August 9, 1962, corroborates their credibility. The risk of mistake or dishonesty is reduced given the multiple publications by different sources.
See United States v. Bell,
Fourth, the newspaper articles were written and published nearly contemporaneously with the events in question.
See United States v. Sinclair,
Fifth, the issue of product identification presented in this case is a “binary event”: either Pfizer supplied the doses, or it did not.
Jacobson v. Deutsche Bank, A.G.,
(2). Notice
Pfizer has been made aware of the Hicks’’ intention to present these newspaper articles as evidence sufficiently in advance of trial so as to obviate the dangers' of prejudice and unfair surprise. While the Hicks have not complied explicitly with the requirement of
Courts have disagreed about whether the notice provision in
Under these circumstances, exacting compliance with the technical requirements of
(3). Necessity and Materiality
The articles are both necessary and material to the Hicks’ case. See
(4). Purposes of the Rules
Finally, admitting these newspaper articles serves “the general purposes of [the Federal Rules of Evidence] and the interests of justice.”
III. Conclusion
The four newspaper articles, admitted under